Bionano Genomics (BNGO) Cash & Equivalents (2017 - 2026)

Bionano Genomics' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 6.21% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $3.4 million (down 6.21% YoY), while the FY2025 annual figure was $3.0 million, down 67.4% from the prior year.
• Cash & Equivalents came in at $3.4 million for Q1 2026 at Bionano Genomics, up from $3.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $34.6 million in Q3 2023 to a low of $3.0 million in Q4 2025.
• A 5-year average of $12.8 million and a median of $9.2 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 93.36% in 2022 and jumped 283.99% in 2024, its largest moves.
• Bionano Genomics' Cash & Equivalents stood at $5.1 million in 2022, then surged by 252.54% to $17.9 million in 2023, then plunged by 48.89% to $9.2 million in 2024, then sank by 67.4% to $3.0 million in 2025, then grew by 13.71% to $3.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.4 million, $3.0 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison